Pre-earnings options volume in Reviva Pharmaceuticals Holdings is normal with calls leading puts 2:1. Implied volatility suggests the market is anticipating a move near 10.5%, or 65c, after results are released. Median move over the past eight quarters is 15.2%.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVPH:
- Reviva Pharmaceuticals Holdings, Inc. (RVPH) Q3 Earnings Cheat Sheet
- Reviva Pharmaceuticals price target raised to $20 from $10 at H.C. Wainwright
- Reviva data robust across multiple endpoints, says Roth MKM
- Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
- Reviva Pharmaceuticals announces Phase 3 RECOVER trial met primary endpoint